Evidence — VIP
peptide · asset evidence level: observational
Evidence quality breakdown (linked documents)
expert_opinion: 14
Linked source documents (14)
- VIP — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- TA1 — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Semax — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Selank — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- PT-141 — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Oxytocin Acetate — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- KPV — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Glutathione — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Kisspeptin-10 — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Glutathione — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- VIP — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- LL-37 — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- KPV — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Vasoactive Intestinal Peptide (VIP) in CIRS Contexts (internal_protocol · expert_opinion)
Provider dosing references (Stage 9, source-attributed)
50 mcg per spray intranasally, up to 4 times daily (titrate per CIRS protocol; typically after correcting other abnormalities) — Practitioner Peptide Dosing Reference (commonly published ranges)
50 mcg per spray, 4-8 sprays daily (CIRS/nasal); 50-150 pmol/kg/min (IV infusion) — Peptide Protocol Wiki (peptideprotocolwiki.com)
Standard: 100 mcg · Low: 50 mcg · High: 200 mcg — Peptide Dosing Protocols (peptidedosingprotocols.com)
Dosing claims (65) · Safety claims (30)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.